SCHEMBL2802693

SCHEMBL2802693

CS(=O)(=O)NC(=O)c1cnn2c(NCc3ccccc3)c(C(=O)N3CCC(c4ccc(F)cc4)CC3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
STAT6 P42226 1/20 0.39
CHRM4 P08173 1/20 0.39
ENPP2 Q13822 1/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 1/20 0.38
CCR1 P32246 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PRKAA2 P54646 1/20 0.37
EGLN1 Q9GZT9 2/20 0.37
SCN7A Q01118 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799687 0.94 STAT6 (0.40) STAT6ENPP2ALDH1A1LMNASMN1; SMN2
SCHEMBL2802391 0.93 SMN1; SMN2 (0.41) TP53STAT6ENPP2ALDH1A1LMNA
SCHEMBL2800864 0.92 CCR1 (0.42) TP53STAT6CHRM4ENPP2CCR1
SCHEMBL2800890 0.92 NTRK1 (0.40) TP53CHRM4ALDH1A1EGLN1SCN7A
SCHEMBL2798553 0.91 THRB (0.37) TP53STAT6ENPP2ALDH1A1LMNA
SCHEMBL2800838 0.90 CHRM4 (0.43) TP53STAT6CHRM4ENPP2ALDH1A1
SCHEMBL2800914 0.89 RBP4 (0.41) TP53CHRM4ALDH1A1MAPTEGLN1
SCHEMBL2802186 0.89 VNN1 (0.43) ALDH1A1
SCHEMBL2804072 0.88 STAT6 (0.41) STAT6ENPP2ALDH1A1LMNASMN1; SMN2
SCHEMBL2802824 0.88 STAT6 (0.39) STAT6ENPP2ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 TP53 241/4885GPBAR1 3277/4885STAT6 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.